Navigation Links
GENova Biotherapeutics signs collaboration agreement with Prime BioResearch
Date:9/15/2009

NEW YORK, Sept. 15 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics Inc. ("GENova") today announced that it has signed a collaboration agreement with Prime BioResearch, Ltd. ("Prime BioResearch") the agreement is focused on how personalized medicine can be applied to cure cancer.

Prime BioResearch specializes in personalized medicines, which involve the use of targeted therapies based on a patient's genetics to cure underlying diseases; this market is undergoing a revolution at the moment and is expected to be a USD5bn+ industry within the next 5 years. The deal between GENova and Prime BioResearch will put GENova to the forefront on personalized cancer treatments and enable GENova to carve out a percentage of this market over the next coming years.

"Prime BioResearch knows that each patient is unique, and that not every person with the same disease responds to each drug in exactly the same way, "Says Aaron Whiteman, CEO for GENova. "They use biomarker information to determine a patient's potential responsivenes to each drug and to maximize treatment and eliminate possible adverse reactions."

The two companies are both in the business of acquiring early-stage developmental drugs, and out-licensing them for development and commercialization, and garnering royalty payments in the process. GENova's focus is oncology, while Prime BioResearch specializes in Obesity, Type 2 Diabetes and other metabolic disorders. They are confident that through scientific collaboration in the field of personalized medicines, they will expedite their drug development activities and subsequently add hundreds of millions of dollars to the bottom line by licensing the technology to companies like Pfizer, Merck, Eli Lilly, Sanofi, Roche, and GSK.

About Prime BioResearch

Prime BioResearch Ltd. is in the business of identifying, evaluating and acquiring potential blockbuster developmental drugs in medical markets with significant growth potential. Prime BioResearch currently has a proprietary portfolio of six worldwide patents in Obesity and Diabetes-II with of $2.9 billion, if successfully brought through development, clinical trials, and to market (Source: PriceWaterhouseCoopers). The Company's mission is to make safe and effective drugs available to the public, quickly and at affordable levels.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec. Visit GENova online at: www.genovabio.com.

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.


'/>"/>
SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. GENova Biotherapeutics and Prime BioResearch signs LOI on diabetes and cancer cure
2. GENova gains access to Big Pharma
3. GENova appoints Dr. Wang Chong to Scientific Advisory Board
4. GENova appoints Dr. Philip Gould to Scientific Advisory Board
5. GENova issues clarifying press release
6. GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees
7. GENova files patent for new breast cancer treatment
8. GENova appoints Director of Asian business development
9. GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum
10. GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board
11. Genova files patent for new prostate cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... ... In Madeira Beach Florida, a small town with 4,300 residents on a ... Madeira Beach United, to oppose two development projects undertaken by their city government that ... rise urban environment. , According to the Tampa Bay Times on May ...
(Date:5/26/2016)... ... May 26, 2016 , ... HealthPostures, ergonomics designer and ... , furniture that may support women during pregnancy. Potential benefits of using the Stance ... rest and comfort and healthier levels of sitting and standing. , Need for the ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... Association/American Stroke Association's Get With The Guidelines®-Stroke Gold Plus Achievement Award with ... second for Memorial Healthcare System, recognizes its commitment to emergency stroke care ...
(Date:5/25/2016)... ... May 25, 2016 , ... Serenity Recovery, a ... video highlighting one of the many supplemental program options offered at their rehabilitation ... 5 th Degree Black Belt in the Shorin-ryu style of Karate that originated ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... Program (KOHP), a $500,000 two-year pilot initiative to improve oral health-related awareness, education, ... professional development for health care providers and promote best practices in 10 New ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 2016  NxStage Medical, Inc. (Nasdaq: NXTM ... renal care, today announced that Jeffrey H. Burbank ... following schedule of investor conferences. Where applicable, a webcast ... http://ir.nxstage.com/ .   ... NY           Friday, June 10, 2016 1:30 p.m. ET ...
(Date:5/24/2016)... , May 24, 2016  Joe Marziani has joined VMS BioMarketing as senior vice ... officer, today. In his new role, Marziani will lead the company,s business development and ... to improve outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... KONG , May 24, 2016 ... stent de doble terapia del mundo, introduce catéteres ... arteriovenosa. OrbusNeich, una compañía global especializada ... las vidas, ha expandido su cartera incluyendo productos ... balón JADE™ y Scoreflex™ PTA son los dispositivos ...
Breaking Medicine Technology: